IRS2 and ovarian carcinoma: It was reported that miRNA-338-3p could directly target PREX2a, MACC1, Rab14, RAB23, IRS2, and Sox4 in ovarian cancer, gastric cancer, breast tumor, prostate cancer, non-small cell lung cancer, glioblastoma, and neuroblastoma [13,14,15,16,17,18].